Mesothelioma News and Research

RSS

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

Researchers find how NF2 gene mutations lead to out-of-control cellular proliferation

A team of Massachusetts General Hospital Cancer Center researchers has determined one way that mutations in a gene involved in a rare, hereditary cancer syndrome lead to out-of-control cellular proliferation.

29 Aug 2018

Inhibition of miR-24-3p may serve as potential treatment target for mesothelioma

Inhibition of miR-24-3p reduced growth of cancer cells and was found to regulate proteins as a potential treatment target for Mesothelioma.

25 Aug 2018

Study finds increase in lifestyle-related cancers over the past decade

Lifestyle-related cancers, such as lung, colorectal, and skin cancers, have increased globally over the past decade, according to the most comprehensive analysis of cancer-related health outcomes and patterns ever conducted.

4 Jun 2018

International researchers succeed in stopping growth of mesothelioma in model animals

An international team led by researchers from the Technion-Israel Institute of Technology and NYU Langone Health have succeeded in stopping the growth of mesothelioma in model animals by inhibiting the heparanase enzyme.

24 May 2018

Combined treatment prolongs survival in mouse models of malignant mesothelioma

Combined treatment with two cancer immunotherapy drugs - one a novel immune modulator and one that focuses and activates the antitumor immune response - significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.

2 Apr 2018

Molecular inhibitors found to arrest tumor cell proliferation in lung cancer and mesothelioma

Inhibition of the oncogenic kinase AKT, a key protein governing the cell cycle, was found to arrest cancer cell proliferation and triggered their programmed death by apoptosis.

2 Apr 2018

Lesser-known CRS-HIPEC treatment for cancers that have spread to abdominal cavity

While cancer treatment advances are being made in the areas of precision medicine and immunotherapy, a unique combination of traditional therapies can also provide some cancer patients a treatment option that may provide significant benefit.

11 Feb 2018

Study findings could lead to less expensive and more effective cancer treatments

The latest generation of cancer treatments spring from the discovery that the human immune system is able to beat the disease. Like Dorothy in "The Wizard of Oz," what research teams around the world have spent decades searching for was right in their own backyard all along.

20 Dec 2017

Novel approach could help predict how well patients respond to cancer treatment

A novel approach developed by researchers from the University of Leicester and the MRC Toxicology Unit could help to predict how well patients respond to drugs designed to fight various forms of cancer.

8 Nov 2017

New report highlights global burden of pollution-related disease and death

Pollution is linked to an estimated nine million deaths each year worldwide – equivalent to one in six (16%) of all deaths, according to a major new report in The Lancet.

20 Oct 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

BWH researchers identify new rare genetic cause of peritoneal mesothelioma

Mesothelioma is a rare and aggressive tumor that, in many cases, results from exposure to asbestos. But over the last several decades, other causes of the disease have emerged, including treatment with high-intensity therapeutic radiation and, more recently, an inherited genetic mutation.

14 Sep 2017

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented today at the ESMO 2017 Congress in Madrid.

11 Sep 2017

Scientists reveal role of cellular prion protein in development of NF2-related tumors

New research published today, 10th July 2017, online in the journal Oncogene could offer hope to the thousands of, mainly young, people affected by the hereditary condition Neurofibromatosis 2 (NF2).

10 Jul 2017

New clinical trial offers hope for patients with hard-to-treat cancer caused by asbestos

Patients with a hard-to-treat type of cancer are being given new hope in a ground-breaking clinical trial. Researchers at the University of Southampton and the University of Leicester are trialing a drug that could boost the body's immune system to fight off mesothelioma, which can be caused by asbestos.

19 May 2017

Scientists establish process for identifying biomarkers for cancer diagnosis

Scientists at Ruhr-Universität Bochum have established a process for identifying biomarkers for the diagnosis of different types of cancer.

3 Apr 2017

Combination of TTFields with standard therapies may improve survival in pancreatic cancer patients

Novocure announced today results from the second cohort of its phase 2 pilot PANOVA trial studying Tumor Treating Fields (TTFields) in combination with nab-paclitaxel and gemcitabine for the treatment of advanced pancreatic cancer.

31 Mar 2017

Phase 2 study shows encouraging results for TTFields therapy in treating recurrent ovarian cancer

Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.